Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Accounts Payables (2018 - 2025)

Summit Therapeutics' Accounts Payables history spans 8 years, with the latest figure at $22.2 million for Q3 2025.

  • For Q3 2025, Accounts Payables rose 584.04% year-over-year to $22.2 million; the TTM value through Sep 2025 reached $22.2 million, up 584.04%, while the annual FY2024 figure was $4.6 million, 73.83% up from the prior year.
  • Accounts Payables reached $22.2 million in Q3 2025 per SMMT's latest filing, down from $23.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $23.0 million in Q2 2025 to a low of $355000.0 in Q4 2022.
  • Average Accounts Payables over 5 years is $5.7 million, with a median of $4.1 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: crashed 91.88% in 2022, then skyrocketed 797.32% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $4.4 million in 2021, then plummeted by 91.88% to $355000.0 in 2022, then soared by 651.27% to $2.7 million in 2023, then skyrocketed by 73.83% to $4.6 million in 2024, then surged by 379.83% to $22.2 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Accounts Payables are $22.2 million (Q3 2025), $23.0 million (Q2 2025), and $5.0 million (Q1 2025).